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In prostate carcinoma (PCa) increased DNA methylation (‘hypermethylation’) occurs at specific genes such as GSTP1. Nevertheless,
overall methylation can be decreased (‘hypomethylation’) because methylation of repetitive sequences like LINE-1 retrotransposons
is diminished. We analysed DNA from 113 PCa and 36 noncancerous prostate tissues for LINE-1 hypomethylation by a sensitive
Southern technique and for hypermethylation at eight loci by methylation-specific PCR. Hypermethylation frequencies for GSTP1,
RARB2, RASSF1A, and APC in carcinoma tissues were each 470%, strongly correlating with each other (Po10
 6). Hypermethylation
at each locus was significantly different between tumour and normal tissues (10
 11oPo10
3), although hypermethylation, particularly
of RASSF1A, was also observed in noncarcinoma tissues. ASC1 hypermethylation was observed in a subgroup of PCa with concurrent
hypermethylation. Hypermethylation of CDH1, CDKN2A, and SFRP1 was rare. LINE-1 hypomethylation was detected in 49% PCa, all
with hypermethylation at several loci. It correlated significantly with tumour stage, while hypermethylation was neither related to
tumour stage nor Gleason score. Coordinate hypermethylation of several genes may occur early in PCa, with additional
hypermethylation events and LINE-1 hypomethylation associated with progression. Hypermethylation allows detection of 482% of
PCas. PCa may fall into three classes, that is, with few DNA methylation changes, with frequent hypermethylation, or with additional
LINE-1 hypomethylation.
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In many human tumours, two different types of alterations of DNA
methylation are found, termed ‘hypermethylation’ and ‘hypo-
methylation’. At specific sites in the genome methylation is
increased, typically in CpG islands around the transcriptional start
sites of genes silenced in tumours (Baylin and Jones, 2002).
Although hypermethylation occurs to some extent during ageing
and in preneoplastic tissues, dense methylation of CpG islands is
largely tumour-specific and can be exploited for tumour detection.
Hypermethylation is frequent in prostate carcinoma (PCa). For
instance, hypermethylation of the GSTP1 gene occurs in 470% of
PCa and has been shown to be useful for its detection (Lee et al,
1994; Esteller et al, 1998; Millar et al, 1999; Santourlidis et al, 1999;
Goessl et al, 2001; Jeronimo et al, 2001; Nakayama et al, 2004).
Hypermethylation of this gene is established during the initial
stages of PCa development (Brooks et al, 1998). Several other
genes, such as APC, CDH1, CDKN2A, RASSF1A, and RARB2 (Graff
et al, 1995; Jarrard et al, 1997; Nakayama et al, 2001; Liu et al, 2002;
Maruyama et al, 2002; Yamanaka et al, 2003), have been reported
to be hypermethylated in prostate cancer with various frequencies
(reviewed in Schulz and Seifert, 2003). Further genes have been
reported as hypermethylated in other human cancers, but have not
been studied in PCa. They include the WNT signalling modulator
gene SFRP1 (Suzuki et al, 2002) at 8p12, a common region of
chromosome loss in PCa (Dong, 2001), and the putative apoptosis
regulator gene ASC1/TMS1 (Conway et al, 2000) at 16p12.
An important question is how multiple hypermethylation events
relate to tumour progression. One possibility is that genes become
successively hypermethylated with carcinoma progression, resulting
in an increase in the number of methylation changes during tumour
development. A second possibility is that PCa may display patterns
of methylation changes related to their biological behaviour,
implicating that patterns of DNA methylation changes might be
associated with different clinical courses. Two recent studies on PCa
have yielded discrepant results on these issues (Maruyama et al,
2002; Yamanaka et al, 2003). A third possibility is that carcinomas
fall into different subclasses, one of which is characterised by a high
frequency of methylation alterations. A precedent is the
CIMPþsubclass of colon cancers (Toyota et al, 2000).
In spite of hypermethylation at specific sites, the overall
methylcytosine content in human tumour cells is often decreased
(‘global’ or ‘genome-wide’ hypomethylation) because methylation
of repetitive sequences such as retroelements and CpG-rich
satellites, which contain most of the methylcytosine in normal
somatic cells, is diminished (Robertson, 2001; Baylin and Jones,
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y2002; Ehrlich, 2002). In particular, LINE-1 retrotransposons
comprise 17% of the human genome and contain a dispropor-
tionate fraction of methylcytosine. The methylation status of LINE-
1 sequences therefore provides a good indicator of global
hypomethylation in tumour cells. Moreover, LINE-1 hypomethyla-
tion may lead to re-expression of individual elements and promote
genomic instability (Florl et al, 1999; Schulz et al, 2002). In PCa,
overall DNA methylation and LINE-1 methylation are decreased
most consistently in metastatic cases (Bedford and van Helden,
1987). The precise relationship between specific hypermethylation
events and global hypomethylation in PCa has not been studied.
Here, we have investigated 113 PCas for hypermethylation at
eight loci by methylation-specific PCR (MS-PCR) and for LINE-1
methylation as an indicator of global hypomethylation by Southern
blot hybridisation. The results suggest that with regard to DNA
methylation alterations PCas may fall into different subclasses.
MATERIALS AND METHODS
Tissues
PCa specimens were obtained between 1993 and 2002, almost all by
radical prostatectomy. Carcinoma and morphologically normal
areas of the prostate were identified, and specimens collected by a
pathologist, rapidly frozen in liquid nitrogen and stored at  801C.
Since several micrograms of high molecular weight DNA were
required for LINE-1 hypomethylation analysis and multiple,
repeated MS-PCR assays, no microdissection was performed.
Immediately after surgical removal, prostates were sectioned by an
experienced pathologist. Tumour and matched tumour-free speci-
mens were only collected (i) when tumours were grossly apparent
in the peripheral zone and could be unequivocally identified by
their characteristic yellow or orange-yellow colour and (ii) when
the transition zone was macroscopically free of tumour burden.
Representative samples of 3mm maximal diameter of tumour and
tumour-free tissue specimens were collected, immediately snap
frozen in liquid nitrogen and stored at  801C. Noncancerous
tissue samples were taken from areas of the transition zone as far
away as possible from the grossly apparent tumour (i.e. in general
from the transition zone of the contralateral lobe). Macroscopic
separation between tumour and nontumorous tissues was
histologically verified by analysing tissue specimens immediately
adjacent to the specimens collected for methylation analysis. TNM
classification was performed according to the guidelines of the
International Union Against Cancer (UICC) from 1997. Of 113 PCa
tissues, 48 carcinomas were staged as pT2, 59 as pT3, and five as
pT4, one tumour was staged as pT1. Lymph node metastases were
present in 21 patients, and distal metastases were detected in one
patient. Four tumours had Gleason scores o5, 77 of 5–7, and 32 of
47. The patients’ mean age was 66 years, ranging from 46 to 79
years. Overall, 36 carcinoma-free tissues were investigated, of
which seven were obtained by adenomectomy or cystoprostatect-
omy for bladder cancer. The study was approved by the ethics
committee of the Heinrich-Heine University medical faculty.
Cell lines
The bladder carcinoma cell line T24 was used as a positive control
for methylation of CDH1, CDKN2A, and SFRP1. The PCa cell line
LNCaP was used as a positive control for methylation of APC,
ASC1, GSTP1, RARB2, and RASSF1A.
DNA extraction
High molecular weight genomic DNA from tissue, cell lines, and
whole blood was isolated using the blood and cell culture DNA kit
(QIAGEN, Hilden, Germany). Frozen tissues were crushed to a fine
powder with a mortar and pestle before extraction.
Methylation-specific PCR
In all, 1mg of DNA from each sample was bisulphite-treated using
the CpGenomet DNA Modification Kit (Oncor, Heidelberg,
Germany) and 80ng each were used in separate PCR reactions
with primer pairs specific for methylated or unmethylated DNA
(Supplementary Table). PCR reactions were performed in a volume
of 50ml containing 1.5mM MgCl2, 150mM dNTPs, 0.6mM of each
primer, and 1.25U HotStar Taq polymerase (QIAGEN). The initial
denaturing step at 951C for 15min was followed by 35–38 cycles
each consisting of a denaturing step at 941C for 30s, primer
annealing at 53–651C (Supplementary Table) for 30 and a 45s
elongation step at 721C. The final 721C period was extended to
8min. PCR products were separated on 2% agarose gels and
visualised by ethidium bromide. Results were scored by two
independent observers. All assays were repeated at least twice with
independent bisulphite treatments and concordant results.
For bisulphite sequencing PCR products were subcloned into
the PCR-4-TOPO vector (Invitrogen, Groningen, NL, USA) and
several clones each were sequenced by standard methods.
LINE-1 hypomethylation analysis
Aliquots from the same DNA were employed to detect LINE-1
hypomethylation. In all, 1mg of high molecular weight DNA each
was extensively digested with the methylation-sensitive restriction
enzyme HpaII or its methylation non-sensitive isoschizomer MspI,
separated on agarose gels, blotted and hybridised with a
32P-
labelled specific LINE-1 probe. After HpaII digestion, decreased
methylation of LINE-1 sequences results in the appearance of new
bands in the 1.0–4.0kb range on Southern blots whose intensities
relative to the MspI signals, after correction for unequal loading of
the two lanes, can be used to quantitate hypomethylation. This
method detects as little as 1% hypomethylation (Florl et al, 1999;
Santourlidis et al, 1999). For categorisation, 0–4% hypomethyla-
tion was considered unchanged (0), 5–12% as moderate (1) and
412% as strong (2), slightly modified from a previous report
(Schulz et al, 2002).
Mathematical procedures
Statistical analyses were performed using S-Plus 4.5. Professional,
Release 2, MathSoft Inc., and MatLab, version 6.1.0.450 (R12.1),
The Math Works, Inc. For CART analysis no weights were used.
Hierarchical clustering was calculated based on Euclidean distance
and average linkage.
RESULTS
Hypermethylation was investigated at eight loci in 113 PCa
specimens using published validated MS-PCR methods (Supple-
mentary Table). Six of these loci had previously been reported to
be hypermethylated in prostate cancers, whereas ASC1 and SFRP1
had been reported as frequently hypermethylated in other cancers,
but not been studied in prostate cancer before. They were chosen
to be located on different chromosomes (with the exception of
RARB2 and RASSF1A), and to represent a wide range of
established or presumed functions. In each MS-PCR assay controls
were carried through the procedure, that is, DNA from a cell line
with hypermethylation of the respective gene as a positive control
and DNA from normal blood leukocytes as a negative control
(Figure 1).
The eight loci fell into three groups with regard to hypermethy-
lation in PCa tissues. First, for APC, GSTP1, RARB2, and RASSF1A
hypermethylation was frequent and found in 78, 79, 70, and 78% of
the cases, respectively. Methylation at each of the four loci strongly
correlated highly significantly with that at any of the other loci.
Thus, 68 (60%) PCa specimens exhibited methylation at all four
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yloci, while in 10 (9%) cases none of the loci was hypermethylated
(Figure 2A). In addition, 10 PCa specimens displayed methylation
in only one gene, most often in RASSF1A, followed by APC. This
distribution is highly unlikely to arise by chance (Po10
 6) and
suggests a coordinate process. Secondly hypermethylation of
CDH1, CDKN2A, and SFRP1, was rare in PCa tissues (o5% of
the specimens), although they were hypermethylated in cancer cell
line controls (Figure 1). This result was not due to lack of
sensitivity, since dilution experiments with T24 cell line DNA
showed that the MS-PCR method detected E1% hypermethylated
alleles for each gene (data not shown). Moreover, the data for
SFRP1 were confirmed by bisulphite sequencing in several positive
and negative samples (data not shown). Thirdly, hypermethylation
of ASC1 was found in 40% of PCa. Interestingly, these also
displayed hypermethylation in at least three of the genes APC,
GSTP1, RARB2, and RASSF1A. Thus, the PCa specimens with ASC1
hypermethylation formed a precise subgroup of those with
concomitant hypermethylation of these four genes (Figure 2C).
Many noncarcinoma prostate specimens were free of hyper-
methylation, but some yielded signals in MS-PCR analyses. In
these, the most frequently hypermethylated gene was RASSF1A
(53%), followed by APC (36%), while hypermethylation of GSTP1
(19%) and RARB2 (17%) was infrequent. This is the same order as
in tumour tissues with hypermethylation of only a single gene.
Importantly, concomitant hypermethylation of several genes was
much rarer in noncarcinoma than in carcinoma tissues (Figure 2B).
Since RASSF1A was most frequently methylated in noncarcino-
ma tissues, its methylation pattern was compared between several
normal and tumour specimens by bisulphite sequencing (Figure 3).
In tumour tissues (T#232 and T#139), individual RASSF1A alleles
were often continuously methylated. In the corresponding normal
tissues (N#233 and N#140), methylation of individual alleles was
less dense. Tumour tissues reacting weakly positive in MS-PCR
(T#133 and T#137) showed patchy methylation and methylation
was rare in the corresponding normal tissues (N#134 and N#138).
One prostate sample without carcinoma from an adenomectomy
for benign hyperplasia and one from a cystoprostatectomy for
bladder cancer were devoid of methylation (N#234, N#235). A
further carcinoma-free prostate specimen (N#229) obtained by
cystoprostatectomy for bladder cancer showed patchy methylation
in RASSF1A.
Accordingly, among the four frequently hypermethylated genes,
hypermethylation of RASSF1A discriminated least well between
normal and tumour tissues. However, even for this gene the
frequency of hypermethylation was significantly different between
carcinoma and noncarcinoma tissues (p(w
2)¼10
 3). The signifi-
cance levels for other loci were 3 10
 5 (APC), 1.2 10
 6
(GSTP1), and 1.2 10
 10 (RARB2). In a CART analysis, optimal
separation between tumour and normal tissues was achieved using
RARB2 plus GSTP1 hypermethylation. This procedure classified
82% of all cancers correctly, while inclusion of further loci
improved detection marginally to 83% (i.e. by one case). The
specificity of the combination RARB2 plus GSTP1 hypermethyla-
tion was 83%, which was identical to that of RARB2 hypermethyla-
tion alone, similar to that of GSTP1 (81%), and considerably higher
than those of APC (61%) and RASSF1A (47%).
Hypomethylation of LINE-1 sequences (Figure 4) was observed
in 49% of PCa (Figure 5A). In 23 specimens pronounced
hypomethylation (defined as 412%) was observed, while 33
displayed moderate hypomethylation (defined as 5–12%). LINE-1
hypomethylation correlated with hypermethylation of each of the
genes RARB2, RASSF1A, GSTP1, and APC (1.7 10
 6 op(w
2)
o3.2 10
 5). Nevertheless, hypermethylation and hypomethyla-
tion were not entirely concordant, because many cases with
hypermethylation in three or four genes lacked LINE-1 hypo-
methylation (Figure 5A). Thus, like ASC1 hypermethylation, LINE-
1 hypomethylation was essentially restricted to a subgroup of the
cases with concomitant hypermethylation of the four genes
(Figure 2C). ASC1 hypermethylation and LINE-1 hypomethylation
correlated closely with each other (p(w
2)¼6.0 10
 4), but the
subgroups were not identical. These relationships are illustrated by
principal component analysis (Figure 5B), which yielded almost
identical vectors for hypermethylation of each of the four genes,
but separation of the vectors representing ASC1 hypermethylation
in the first component and LINE-1 hypomethylation in the second
component. No significant LINE-1 hypomethylation was seen in
any noncancer prostate specimen analysed (Figure 4).
None of the more frequent hypermethylation events, including
ASC1 hypermethylation, were significantly related to tumour stage
or Gleason score. All six cases with SFRP1 hypermethylation were
staged as pT2 and this rare change was therefore significantly
related to tumour stage (P¼0.02). The number of hypermethyla-
tion events was unrelated to clinical parameters (Table 1). LINE-1
Table 1 Summary of MS-PCR parameters
Gleason score
(a)
# of genes
hypermethylated 1–4 5–7 8–10
P¼0.1781 0–1 3 28 14
2–3 0 15 10
4 1 34 8
Tumour stage
pT1–2 pT3–4
P¼0.2024 0–1 24 21
2–3 10 15
41 5 2 8
Lymph node status
N0 N+
P¼0.4817 0–1 39 6
2–3 19 6
43 4 9
Gleason score
(b) Hypomethylation 1–4 5–7 8–10
P¼0.5937 0–3% 1 40 14
4–12% 2 24 9
412% 1 13 9
Tumour stage
pT1–2 pT3–4
P¼0.04187 0–3% 29 26
4–12% 15 20
412% 5 18
Lymph node status
N0 N+
P¼0.08172 0–3% 47 8
4–12% 30 5
412% 15 8
For each gene the primer sequences used, the annealing temperatures, and the
number of cycles are indicated. M¼methylated-specific primers; U¼unmethylated-
specific primers; BS¼primers used for bisulphite sequencing.
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carcinomas (P¼0.04) and tended to be more pronounced in
lymph node-positive PCa (P¼0.08).
DISCUSSION
Hypermethylation of GSTP1 is a promising marker for detection of
PCa (Lee et al, 1994; Esteller et al, 1998; Millar et al, 1999;
Santourlidis et al, 1999; Goessl et al, 2001; Jeronimo et al, 2001).
Different studies have reported somewhat different proportions of
positive cancers, likely due to differences in methodology as well as
to differences between the patient populations investigated. Here,
using a sensitive MS-PCR method, we found 70% of carcinoma
tissues from a Central European population to display GSTP1
hypermethylation with rare methylation in adjacent normal
tissues, supporting its value as a marker. In the same specimens,
three further genes, that is APC, RARB2, and RASSF1A, proved to
be hypermethylated at similarly high frequencies, and also
discriminated well between tumour and normal tissue. A
combination of several genes may be optimal for discrimination
and could be used as described here or in combination with
quantitative methylation analyses (Jeronimo et al, 2001). In our
data set, optimal separation between carcinoma and normal tissues
was achieved by GSTP1 and RARB2 hypermethylation, identifying
480% tumour samples correctly. The specificity of detection by
this combination was 83% and thus not exceedingly high.
However, as the noncarcinoma specimens were mostly taken from
prostates that harboured cancers, this level of specificity is likely
an underestimate (see discussion below).
The fact that two of these four genes are sufficient to detect all
carcinomas with hypermethylation follows from the strong
correlation between hypermethylation of these individual genes.
If each hypermethylation event occurred independently at the
observed frequencies (70–79%), most carcinomas should display
hypermethylation in two or three genes and o1/113 should lack
hypermethylation. Therefore, we observed more tumours with
simultaneous hypermethylation of all four genes as well as more
tumours without hypermethylation at any of the loci than expected
from a stochastic process (cf Figure 2). This suggests that
hypermethylation occurs in a coordinate manner in most cases
and, conversely, that a smaller subset of PCas is not prone to
hypermethylation. It may be difficult to distinguish PCa in this
subset reliably from normal or ageing prostate by DNA methyla-
tion analysis. There is so far little indication for major differences
in clinical course between the hypermethylation-prone and rare-
hypermethylation groups (Supplementary Table). This fits the
emerging consensus that deregulation of DNA methylation can be
RASSF1A
APC
SFRP1
CDH1
CDKN2A
RARB2
GSTP1
U-Control
M-Control
#26
#227
#177
#119
#195
#173
#211
#125
#157
#203
H 2 O
UMUMUMUMUMUMUMUMUMUMUMUMUM
ASC
Figure 1 Methylation specific PCR. Representative examples of MS-PCR analyses for the methylated (M) and the unmethylated (U) forms of eight genes
in prostate cancer. Selected tumour samples with decreasing frequency of hypermethylation events from left to right. The bladder cancer cell line T24 was
used as a positive control for CDH1, CDKN2A, and SFRP1 hypermethylation. The prostate carcinoma cell line LNCaP was used for ASC1, APC, GSTP1, RARB2,
and RASSF1A hypermethylation (M control). Leukocyte DNA from a female without cancer was used as a negative control (U control).
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yas effective at driving tumour development and progression as
chromosomal instability or base repair deficiency (Baylin and
Jones, 2002).
The strongly coordinated hypermethylation of the above four
genes is remarkable in view of the low hypermethylation rate
detected in three other genes that are often hypermethylated in
other cancers. Our data on CDKN2A/p16 are in accordance with
other reports on a low percentage of hypermethylation of this gene
in PCa (Jarrard et al, 1997; Maruyama et al, 2002). The reported
frequencies of CDH1 hypermethylation in PCa differ widely
between published studies (Graff et al, 1995; Woodson et al,
2003). Detailed analyses have shown hypermethylation patterns in
CDH1 to be very variable (Graff et al, 2000), which may partly
explain these differences. At any rate, such a variability would
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Figure 2 Hypermethylation in prostate cancer and noncancerous tissues. (A) Number of cases with hypermethylation detected in the indicated number
of genes (APC, GSTP1, RARB2, and RASSF1A) in PCa tissues. (B) Number of cases with hypermethylation detected in the indicated number of genes (APC,
GSTP1, RARB2, and RASSF1A) in prostate tissues morphologically free of carcinoma. (C) Cluster analysis of APC, ASC1, GSTP1, RARB2, RASSF1, and SFRP1
hypermethylation in PCa tissues. Black: hypermethylated; grey: unmethylated. LINE-1 hypomethylation is also shown. Black: hypomethylation 44%; grey:
normal methylation.
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Figure 3 Bisulphite methylation analysis of RASSF1A. Methylation status of the RASSF1A promoter CpG island in paired prostate carcinoma (T) and
adjacent normal (N) tissue samples (#232/233, #133/134, #137/138, #139/140) as well as carcinoma-free prostate specimens obtained during
adenomectomy for benign prostate hyperplasia (AD, #234) or cystoprostatectomy for bladder cancer (Cy, #229 and #235). Each circle depicts an
individual CpG site. Black: methylated site, white: unmethylated site. At the top of the figure, the localisation of the 22 investigated sites in the RASSF1A
promoter are indicated. Several potential binding sites for Sp1 are marked by asterisks.
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found in other cancers (Suzuki et al, 2002), but had not been
studied before in PCa. This gene was of particular interest because
of its location in a chromosomal region with a high frequency of
allelic loss in PCa (Dong, 2001). In this regard, our data indicate that
the gene may become inactivated by hypermethylation in individual
cases of PCa. Our data suggest a more significant involvement of
ASC1. This gene has previously been identified as being silenced by
hypermethylation in breast carcinoma and is thought to be involved
in the regulation of apoptosis (Conway et al, 2000). Its precise role
in PCa certainly deserves further investigation.
The comparison of the two groups of genes – APC, GSTP1,
RARB2, and RASSF1A vs CDH1, CDKN2A, and SFRP1 – suggests
no obvious explanation why they should become hypermethylated
at such different frequencies. Specifically, GSTP1, RARB2, APC,
and RASSF1A are not known to function in a common pathway or
– with the exception of RARB2 and RASSF1A – reside on the same
chromosome. Our data call for a mechanistic explanation of this
unexpected specificity.
In the course of PCa, the origin of GSTP1 hypermethylation has
been traced to late preneoplastic stages like high-grade prostatic
intraepithelial neoplasia (Brooks et al, 1998; Yamanaka et al, 2003)
and proliferative inflammatory atrophy lesions (Nakayama et al,
2003; Yamanaka et al, 2003). If GSTP1 hypermethylation is
associated with the onset of prostate carcinogenesis, it cannot be
related to tumour stage or Gleason score, as observed here and by
others (Yamanaka et al, 2003). Furthermore, because GSTP1
hypermethylation correlated strongly with that of three other
genes, their hypermethylation may also occur at early stages of
cancer development. Moreover, our data suggest that hypermethy-
lation of RASSF1A might begin in preneoplastic tissue. Hyper-
methylation of RASSF1A was most frequently found in normal
tissue from carcinoma-carrying prostates, and RASSF1A was the
locus most often hypermethylated without hypermethylation at
other loci. In addition, RASSF1A methylation on individual alleles
was denser in carcinoma than in normal prostate tissue (Figure 3).
This observation is very reminiscent of findings in the colon.
There, some genes are only hypermethylated in colon carcinoma,
whereas others start to become hypermethylated in ageing and
preneoplastic colon. The patchy methylation in ageing tissue
becomes intensified in tumour cells (Issa, 2000). Our data suggest
that RASSF1A may belong to this class in prostate tissue.
The findings on RASSF1A raise the question of how to interpret
hypermethylation events observed in normal-appearing prostate
tissue. In some cases, hypermethylation might be derived from
minimal carcinoma infiltrates not detected on adjacent histological
sections, particularly, in the few cases where hypermethylation of
several genes was observed (Figure 2B). However, there were
several differences between hypermethylation detected in normal
and carcinoma tissues. First, the order of the frequencies for
different genes was different. GSTP1, RARB2, APC, and RASSF1A
were each hypermethylated in 70–80% of carcinoma tissues,
whereas the order in noncarcinoma tissues was RASS-
F1A4APC4GSTP1¼RARB2. Secondly, concomitant hyper-
methylation was rare in morphologically normal tissues, but was
the rule in carcinomas (Figure 2). Thirdly, the methylation pattern
in RASSF1A was always patchy in non-neoplastic tissues, whereas
dense methylation was typically seen in carcinomas (Figure 3).
Taken together, these results might argue for age-associated
hypermethylation in the prostate like that reported for other
organs (Issa, 2000). Hypermethylation in the prostate might help
to establish a preneoplastic state that disposes to carcinoma
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Figure 4 Southern blot analysis of LINE-1 hypomethylation in prostate and prostate carcinoma tissues. DNA isolated from prostates carrying no
carcinoma (left), carrying carcinoma (center), and from prostate carcinomas (right) was analysed for LINE-1 hypomethylation as described in the Materials
and Methods section. H: HpaII digestion; M: MspI digestion. Hypomethylation is detectable by the appearance of bands in the 1.4–3.5kb range in the H lane.
Results of densitometric quantification (see Materials and Methods for details) are depicted at the bottom of the figure.
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ydevelopment. Indeed, if the silencing of GSTP1 by hypermethylation
was to promote the initial development of PCa by inducing an
increased sensitivity to electrophilic carcinogens, as postulated by
others (Nakayama et al, 2004), one would have to expect methylation
changes to actually precede the development of morphological changes.
Our finding of a lack of correlation between DNA hypermethy-
lation and tumour stage and Gleason grade in the prostate is in
good agreement with a study of Japanese patients (Yamanaka et al,
2003), but differs from the results in an American cohort
(Maruyama et al, 2002) in which the number of methylated genes
increased with tumour stage and Gleason score. The reasons for
these differences may thus be population-related, or may reflect
methodical differences. For instance, the study reporting a good
correlation of hypermethylation with stage and grade detected
GSTP1 hypermethylation in only 36% of PCa tissues, which is by
far the lowest rate reported in the literature.
In our hands, LINE-1 hypomethylation represents the methyla-
tion change best related to histopathological parameters of PCa. In
previous studies, global DNA hypomethylation was found to be
particularly pronounced in specimens from androgen-refractory
carcinomas (Bedford and van Helden, 1987; Schulz et al, 2002).
Accordingly, the present study showed LINE-1 hypomethylation to
be more prevalent in high stage and lymph-node positive PCas.
LINE-1 hypomethylation obviously characterises a set of PCas
within the subclass of those with frequent hypermethylation
(Figures 2C and 4) and is associated with higher stage disease. The
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ymost straightforward explanation for this finding is that LINE-1
hypomethylation in PCa is a secondary event during progression
following DNA hypermethylation. As a corollary, the mechanisms
causing DNA hypermethylation at specific sites and DNA
hypomethylation of repetitive sequences are likely distinct, as also
reported for Wilms tumours (Ehrlich et al, 2002). Another change
occurring during progression may be ASC1 hypermethylation,
which was also found in a precise subgroup of the hypermethyla-
tion-prone cancers, but apparently not the same one exhibiting
LINE-1 hypomethylation. However, no significant relationship to
stage or grade was found for this change.
Our study therefore suggests a distinction of three subclasses of
PCa, one with few DNA methylation changes, one with hyper-
methylation of several genes, and one with additional hypomethy-
lation of repetitive sequences. This last subclass may be over-
represented among high-stage PCa (P¼0.086 in the present study
according to Kruskal–Wallis test). The distinction between these
three subclasses might be useful for further development of
methylation-based diagnosis of PCa.
Finally, regarding the functional implications of our findings,
hypermethylation of promoter sequences is established as a
mechanism of silencing of tumour suppressor genes in human
cancers (Baylin and Jones, 2002). The GSTP1 gene is frequently
hypermethylated in prostate cancers, but is a less than ideal
candidate for a tumour suppressor (reviewed by Nakayama et al,
2004). Its loss of function may lead to increased sensitivity against
certain electrophilic compounds and perhaps decreased apoptosis,
which could promote carcinogenesis in the prostate. The finding in
the present study that hypermethylation of GSTP1 occurs in a
coordinate manner with that of other genes raises the interesting
possibility that GSTP1 hypermethylation might be a bystander
effect of the inactivation of a gene more directly involved.
Specifically, all three other genes found to be coordinately
hypermethylated with GSTP1 in this study, APC, RARB2, and
RASSF1A, are established as functionally important in other
cancers. Regarding the functional implications of hypomethyla-
tion, it has previously been reported to be almost ubiquitous in
metastatic PCa (Bedford and van Helden, 1987, Schulz et al 2002),
in accord with a significant correlation of LINE-1 hypomethylation
with tumour stage in the present study. Moreover, LINE-1
hypomethylation was found to be significantly correlated with
chromosomal instability (Schulz et al, 2002). It is not known,
however, whether genome-wide hypomethylation causes chromo-
somal instability, although there is some experimental support for
this idea (Eden et al, 2003).
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